ADC Therapeutics SA
ADCT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ADCT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ADCT
ADC Therapeutics SA is a commercial-stage global pioneer in antibody-drug conjugates (ADCs), focused on developing and commercializing its lead product ZYNLONTA for hematological malignancies.
Key risk: Regulatory approval risk
BioSniper Score
Based on 6 of 6 signals
Market Cap
$145.5M
Cash Runway
58.9 moLead Asset
ADCT-601 (Phase 1)
Next Catalyst
Phase3_Topline · Jun 30, 2028Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 3 clinical trials · 1 catalyst · 1 FDA decision for ADC Therapeutics SA.
ADC Therapeutics SA is a commercial-stage global pioneer in antibody-drug conjugates (ADCs), focused on developing and commercializing its lead product ZYNLONTA for hematological malignancies.
- Commercial-stage global pioneer in the field of antibody drug conjugates (ADCs) [sec_mda].
- Lead product ZYNLONTA (loncastuximab tesirine) is approved under accelerated approval for relapsed/refractory diffuse large B-cell lymphoma [sec].
- Cash and equivalents of $219.1M as of 2026-06-30 [sec].
- Total revenue of $19.2M and net loss of -$16.6M for the six months ended 2026-06-30 [sec].
- Shareholders' equity of -$185.8M and total debt of $6.2M as of 2026-06-30 [sec].
What works
- Lead product ZYNLONTA is approved under accelerated approval, providing a commercial revenue stream [sec].
- Phase 3 LOTIS-5 trial topline results have been reported, supporting a planned sBLA submission for full regulatory approval [sec · filed 2026-06-03].
- Cash position of $219.1M as of 2026-06-30 provides runway for near-term operations [sec].
What to weigh
- Accumulated deficit and negative shareholders' equity of -$185.8M as of 2026-06-30 indicate ongoing losses [sec].
- Dependence on successful sBLA submission and FDA approval for full regulatory approval of ZYNLONTA [sec · filed 2026-06-03].
- Reliance on external financing, collaborations, or licensing to fund future operations [sec_mda · as of 2026-05-04].
- Net loss of -$16.6M for the six months ended 2026-06-30 reflects continued operating expenses exceeding revenue [sec].
From the filings
Quoted directly from source documents.
ADC Therapeutics is a commercial-stage global pioneer in ADCs.
“ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates ("ADCs").”
SEC MD&A · August 13, 2026
The company plans to submit an sBLA for full approval of ZYNLONTA based on LOTIS-5 results.
“Based on these topline results from LOTIS-5, the Company plans to conduct a pre-Supplemental Biologics License Application ("sBLA") meeting with the U.S. Food and Drug Administration ("FDA") in August and is preparing for a planned sBLA submission in the fourth quarter of 2026.”
SEC filings · June 3, 2026
Cash and equivalents were $261.3M as of December 31, 2025.
“As of December 31, 2025, we had cash and cash equivalents of $261.3 million”
SEC MD&A · March 10, 2026
Catalyst timeline
- 2028-06-30 · Phase3_Topline · loncastuximab — Phase 3 Topline: A Phase 3 Randomized Study of Loncastuximab Tesirine Combined With Rituximab Versus Immunochemothera — Topline results from the Phase 3 LOTIS-5 study are expected, which could support full regulatory approval of ZYNLONTA.
Risks & what to watch (4)›
Key risks
- Regulatory approval risk — Failure to obtain full FDA approval for ZYNLONTA could limit commercial potential [sec · filed 2026-06-03].
- Financial sustainability — Negative shareholders' equity and net losses raise going-concern risk [sec].
- Dependence on financing — Future operations rely on additional equity, debt, or collaboration funding [sec_mda · as of 2026-05-04].
- Clinical trial outcomes — Adverse safety or efficacy data from ongoing trials could impact regulatory path [sec].
What to watch
- Pre-sBLA meeting with FDA in August 2026 and subsequent sBLA submission in Q4 2026 [sec · filed 2026-06-03].
- FDA decision on full approval of ZYNLONTA for relapsed/refractory DLBCL [sec].
- Cash burn rate and any additional financing or collaboration deals [sec_mda · as of 2026-05-04].
- Phase 3 topline results from LOTIS-5 and potential impact on commercial adoption [sec · filed 2026-06-03].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run ADC Therapeutics SA through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ADC Therapeutics SA facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
58.9 months
OCF -$12M · Net income -$17M
Lead: Approved
3 candidates
1 upcoming, next in ~670d
0 buys · 6 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
114
Total value held
$177.5M
| Holder | Shares | Value |
|---|---|---|
| prosight management, lp | 8,300,000 | $31.1M |
| blackrock, inc. | 6,250,747 | $23.4M |
| eventide asset management, llc | 5,701,655 | $21.4M |
| morgan stanley | 3,812,582 | $14.3M |
| millennium management llc | 3,254,154 | $12.2M |
| goldman sachs group inc | 1,653,026 | $6.2M |
| state street corp | 1,566,662 | $5.9M |
| bank of america corp /de/ | 1,325,017 | $5.0M |
| orbimed advisors llc | 1,318,026 | $4.9M |
| geode capital management, llc | 1,203,756 | $4.5M |
Showing top 10 of 114 institutional holders of ADC Therapeutics SA. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 4.8%
- Days to cover
- 6.1
- Shares short
- 5,144,704
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ADCT short interestGovernance
Frequently asked questions
What is the AI investment thesis for ADC Therapeutics SA?
ADC Therapeutics SA is a commercial-stage global pioneer in antibody-drug conjugates (ADCs), focused on developing and commercializing its lead product ZYNLONTA for hematological malignancies.
What is ADC Therapeutics SA's lead drug candidate?
ADC Therapeutics SA's most advanced tracked candidate is ADCT-601 (Phase 1) for Evaluated in patients with sarcoma, pancreatic cancer and AXL-expressing non-small cell lung cancer (NSCLC).
What is ADC Therapeutics SA's next catalyst?
ADC Therapeutics SA's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3 Randomized Study of Loncastuximab Tesirine Combined With Rituximab Versus Immunochemothera" — expected June 30, 2028.
Who is the CEO of ADC Therapeutics SA?
Dr. Ameet Mallik M.B.A., M.S. is the chief executive officer of ADC Therapeutics SA (ADCT).
Where is ADC Therapeutics SA headquartered?
ADC Therapeutics SA (ADCT) is headquartered in Epalinges, Switzerland.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.